...

A 36-week, single-arm, open-label study to evaluate the safety and tolerability of ferric citrate in children with hyperphosphatemia related to chronic kidney disease.

To assess the safety and tolerability of ferric citrate in pediatric subjects with hyperphosphatemia related to chronic kidney disease (CKD).

Why this Research Matters

A single arm trial evaluating efficacy of ferric citrate over 36 weeks in pediatric patients with hyperphosphatemia related to CKD.

Who can Participate

Child and Teen

12-17 years old, diagnosis of CKD

Study ID

Protocol Number: 23-0073

Meet the Team

Image of Principal Investigator

Weiwen Shih, MD

Principal Investigator

Categories

Locations